Redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR, supporting redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.
The redo-TAVR cohort consisted of 439 patients with a mean age of 78.9 years, the majority of whom were women.
Redo-TAVR with Evolut valves was associated with low procedural complication rates.
Redo-TAVR reduced transvalvular gradients at 1 year, though gradients remained modestly higher than after native TAVR.
After adjustment, 30-day clinical outcomes including mortality, stroke, and readmission were similar between redo-TAVR and native TAVR.
After adjustment, 1-year clinical outcomes including mortality, stroke, and readmission were similar between redo-TAVR and native TAVR.
Improvements in functional status and quality of life were observed early after redo-TAVR and were sustained through 1 year.
Findings supporting comparable outcomes between redo-TAVR and native TAVR were consistent across prespecified subgroups.
This research suggests that when patients' previously implanted transcatheter heart valves wear out or fail, replacing them with a new transcatheter valve (called redo-TAVR) using a specific self-expanding valve system (the Medtronic Evolut platform) is a safe and effective option. The study analyzed data from 439 patients in a large U.S. national registry and found that the procedure had low complication rates and that patients' rates of death, stroke, and hospital readmission at both 30 days and 1 year were statistically similar to those seen in patients receiving their first-ever transcatheter valve replacement. The study also found that the redo procedure successfully lowered the pressure gradients across the valve (a measure of how hard the heart has to work to push blood through), and that patients experienced meaningful improvements in their quality of life and ability to function, with those gains holding up at the one-year mark. One notable finding is that while pressure gradients improved significantly after redo-TAVR, they remained modestly higher than those seen after native valve replacement, which may be relevant for longer-term monitoring. This research matters because the number of patients with failing transcatheter valves is expected to grow substantially as the TAVR procedure becomes more common and as earlier recipients age. These findings provide real-world evidence that redo-TAVR with this valve platform is a viable treatment strategy for appropriately selected patients, offering outcomes comparable to first-time procedures — an important reassurance for both patients and clinicians planning for this emerging clinical need.
Rogers T, Bapat V, Chetcuti S, Dauerman H, Forrest J, Goel S, et al.. (2026). Redo-Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis.. JACC. Cardiovascular interventions. https://doi.org/10.1016/j.jcin.2026.07.009